Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

I-TECH (Lim)
 
NCT04920942
RCTivermectincontrolCOVID-19 mild to moderatesome concern
241/249 inconclusive
  • inconclusive 25 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
FACCT Trial
 
NCT04392973
RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
125/129 inconclusive
  • inconclusive 15 % decrease in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
Kirti
 
CTRI/2020/08/027225
RCTivermectinplaceboCOVID-19 mild to moderatesome concern
57/58 inconclusive
  • inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
Rashad A (AZI vs SoC) RCTazithromycinstandard of careCOVID-19 mild to moderatesome concern
107/99 inconclusive
    Shinkai
     
    JapicCTI-205238
    RCTfavipiravir placeboCOVID-19 mild to moderatesome concern
    107/49 safety concern
    • inconclusive 40 % increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 18.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
    Solaymani-Dodaran
     
    IRCT20200318046812N1
    RCTfavipiravir lopinavir/ritonavirCOVID-19 mild to moderatesome concern
    193/187 inconclusive
      AVIFAVIR
       
      NCT04434248
      RCTfavipiravir standard of careCOVID 19 hospitalized, COVID-19 mild to moderatesome concern
      20/20 suggested
      • suggested 2.9-fold increase in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
      Adverse drug reactions to AVIFAVIR were reported in 7/40 (17.5%) patients, including diarrhea, nausea, vomiting, chest pain and an increase in liver transaminase levels. The adverse drug reactions were mild to moderate and caused early discontinuation of the study drug in 2/40 (5.0%) patients.
      Chaccour
       
      NCT04390022
      RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
      12/12 inconclusive
      • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias
      COALITION I Covid-19 Brazil (AZI, Cavalcanti)
       
      NCT04322123
      RCTazithromycinstandard of careCOVID-19 mild to moderatesome concern
      172/159 inconclusive
      • inconclusive 18 % decrease in clinical improvement,clinical improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      Dabbous HM
       
      NCT04349241
      RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
      50/50 inconclusive
        ELACOI (Lopinavir/ritonavir)
         
        NCT04252885
        RCTumifenovir (arbidol)lopinavir/ritonavirCOVID-19 mild to moderatesome concern
        35/34 inconclusive
        • inconclusive 84 % increase in viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
        • inconclusive 8 % increase in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
        ELACOI (lopinavir/ritonavir)
         
        NCT04252885
        RCTlopinavir/ritonavirstandard of careCOVID-19 mild to moderatesome concern
        21/7 inconclusive
          GS-US-540-5773 (Goldman)
           
          NCT04292899
          RCTremdesivirremdesivirCOVID-19 mild to moderatesome concern
          200/197 suggested
          • suggested 53 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
          GS-US-540-5774, 10 days
           
          NCT04292730
          RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
          197/200 safety concern
          • suggested 58 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 88 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
          • statistically significant 63 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
          The primary endpoint was not met, no odds ratio is reported because the proportional odds assumption was not met
          GS-US-540-5774, 5 days
           
          NCT04292730
          RCTremdesivirstandard of careCOVID-19 mild to moderatesome concern
          199/200 conclusif
          • demonstrated 65 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
          Hung et al.
           
          NCT04276688
          RCTlopinavir/ritonavir, ribavirin and interferon beta-1blopinavir/ritonavirCOVID-19 mild to moderatesome concern
          86/41 conclusif
          • demonstrated 3.4-fold increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 2.9-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
          Khamis RCTfavipiravir plus interferonstandard of careCOVID-19 mild to moderatesome concern
          44/45 inconclusive
            Krolewiecki
             
            NCT004381884
            RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
            30/15 inconclusive
              Li T
               
              NCT04273763
              RCTbromhexinestandard of careCOVID-19 mild to moderatesome concern
              12/6 suggested
              • inconclusive 52 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
              • suggested 9.0-fold increase in hospital discharge with a moderate degree of certainty due to some concern in risk of bias
              NCT04542694
               
              NCT04542694
              RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
              100/100 suggested
              • suggested 1.1-fold increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
              • suggested 12.0-fold increase in viral clearance with a moderate degree of certainty due to some concern in risk of bias
              Ren
               
              ChiCTR2000029853
              RCTazvudineantiviral and associated therapyCOVID-19 mild to moderatesome concern
              10/10 suggested
              • suggested 27.5-fold increase in viral clearance ,viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
              Ruzhentsova T
               
              NCT04501783
              RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
              112/56 suggested
              • suggested 63 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
              • inconclusive 28 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
              • suggested 28 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
              • suggested 50 % increase in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias
              Shahbaznejad
               
              IRCT20111224008507N3
              RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
              35/38 inconclusive
                Udwadia
                 
                CTRI/2020/05/025114
                RCTfavipiravir standard of careCOVID 19 hospitalized, COVID-19 mild to moderatesome concern
                75/75 safety concern
                • inconclusive 37 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                • suggested 75 % increase in clinical improvement,clinical improvement (time to event analysis only),clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
                • suggested 94 % decrease in mechanical ventilation (time to event analysis only),mechanical ventilation with a moderate degree of certainty due to some concern in risk of bias
                • statistically significant 5.4-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
                16 studies excluded by filtering options (11 RCT / 5 OBS)

                PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).